BLACK WEEKSFlakonai −15% · rinkiniai −10% · kita −5%su koduNemokamas siuntimas Vokietijoje nuo €200

Šis puslapis išverstas automatiškai ir jame gali būti klaidų. Ar lietuvių kalba yra jūsų gimtoji? Mielai sulauksime jūsų atsiliepimų ir pataisymų.Siųsti atsiliepimą

The Peptide Desk The Peptide Desk
Dapagliflozin (Forxiga), produkto nuotrauka
Medication

Dapagliflozin (Forxiga)

Medication

  • Siunčiame iš Vokietijos

Užsakymas

Vieneto kaina - Nemokamas siuntimas Vokietijoje nuo 200 € Black Weeks metu
  • DHL su sekimu
  • Diskreti pakuotė

4.6 iš 5 TrustpilotAtsiliepimų: 73

Trumpai

Dapagliflozin (Forxiga) skaičiais

Pagrindiniai rodikliai iš mūsų žinyno. Vilkite tašką kreive, kad pamatytumėte, kiek lieka po vienos dozės, pagal skaičiavimą.

Visas žinyno įrašas

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~12.9 hours

Half-life ~12.9 hours
After 26 hours: 25 %
Hour 1350 %Hour 24, next dose28 %Hour 2625 %Hour 3912.3 %Hour 653 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Half-life

about12.9hours

Class
SGLT2 inhibitorgliflozin, selective
Use
Oral1x daily
Sizes
10 mg1 size in the shop

Produktui Dapagliflozin (Forxiga) laboratorinės analizės dar nėra. Balsuoti už taiUžsakykite tyrimą, mes apmokame pusęVisos laboratorinės analizės

Žinios

Viskas apie Dapagliflozin (Forxiga)

FAQ

Dažnai užduodami klausimai

Šaltiniai kiekvienam atsakymui: žinyno įrašas

Dar turite klausimų?

Parašykite mums, mūsų komanda jums padės.

How does dapagliflozin work?

It blocks the transporter SGLT2 in the kidney, which brings filtered sugar back into the blood. The sugar then leaves with the urine without insulin being needed. Breakdown runs mainly via the enzyme UGT1A9 to an inactive metabolite.

Does it help without diabetes?

In the trials on heart failure and chronic kidney disease the effect was similar with and without diabetes. With reduced pumping the risk of worsening or cardiac death fell by 26 percent.

What did the kidney trial show?

Among 4,304 participants 9.2 percent on dapagliflozin and 14.5 percent on placebo had an event (halved kidney function, kidney failure or death). 19 had to be treated to prevent one. The trial was therefore stopped early.

What is euglycaemic ketoacidosis?

Acidosis from ketones with nearly normal blood sugar. Because sugar does not rise much, it was recognised late in a case series. The authors advise checking ketones in case of nausea, vomiting or malaise. In the large diabetes trial it occurred in 0.3 versus 0.1 percent.

Does it lower heart attacks and strokes?

Not clearly in the diabetes trial with 17,160 patients: 8.8 versus 9.4 percent major cardiovascular events. Hospital stays for heart failure and kidney events did fall clearly.

Which side effects are known?

Serious genital infections or those leading to a stop occurred in 0.9 versus 0.1 percent, ketoacidosis in 0.3 versus 0.1 percent. In the heart failure trials volume depletion, kidney problems and low blood sugar were not more common than on placebo.

Susiję

Susiję produktai